1. |
Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin, 2023, 73(1): 17-48.
|
2. |
Pergolizzi RG, Brower ST. Molecular targets for the diagnosis and treatment of pancreatic cancer. Int J Mol Sci, 2024, 25(19): 10843. doi: 10.3390/ijms251910843.
|
3. |
何茹, 董仕, 周文策. 胰腺癌分子靶向治疗的研究进展. 中国普外基础与临床杂志, 2022, 29(11): 1534-1540.
|
4. |
Tiwari PK, Shanmugam P, Karn V, et al. Extracellular vesicular miRNA in pancreatic cancer: from lab to therapy. Cancers (Basel), 2024, 16(12): 2179. doi: 10.3390/cancers16122179.
|
5. |
Spiliopoulos S, Reppas L, Filippiadis D, et al. Irreversible electroporation for the management of pancreatic cancer: current data and future directions. World J Gastroenterol, 2023, 29(2): 223-231.
|
6. |
Jeon SM, Davaa E, Jenjob R, et al. The induction of combined hyperthermal ablation effect of irreversible electroporation with polydopamine nanoparticle-coated electrodes. Int J Mol Sci, 2024, 25(8): 4317. doi: 10.3390/ijms25084317.
|
7. |
Geeho M, Soon HC, Woojung K, et al. Development of new endoscopic irreversible electroporation ablation device: animal experimental study. Journal of Clinical Oncology, 2018, 36(4): 188. doi: 10.1200/JCO.2018.36.4_suppl.188.
|
8. |
Faiella E, Santucci D, Vertulli D, et al. Irreversible electroporation (IRE) for prostate cancer (PCa) treatment: the state of the art. J Pers Med, 2024, 14(2): 137. doi: 10.3390/jpm14020137.
|
9. |
Imran KM, Nagai-Singer MA, Brock RM, et al. Exploration of novel pathways underlying irreversible electroporation induced anti-tumor immunity in pancreatic cancer. Front Oncol, 2022, 12: 853779. doi: 10.3389/fonc.2022.853779.
|
10. |
Wada T, Sugimoto K, Sakamaki K, et al. Comparisons of radiofrequency ablation, microwave ablation, and irreversible electroporation by using propensity score analysis for early stage hepatocellular carcinoma. Cancers (Basel), 2023, 15(3): 732. doi: 10.3390/cancers15030732.
|
11. |
何朝滨, 李升平. 不可逆电穿孔治疗胰腺癌. 临床外科杂志, 2024, 32(7): 673-676.
|
12. |
Guo F, Gou X, Sun J, et al. Modeling methods in overlapping electroporation treatments: Pulse number effects on tissue conductivity and ablation area. Electrochimica Acta, 2024, 503: 144883. doi: 10.1016/j.electacta.2024.144883.
|
13. |
Distelmaier M, Barabasch A, Heil P, et al. Midterm safety and efficacy of irreversible electroporation of malignant liver tumors located close to major portal or hepatic veins. Radiology, 2017, 285(3): 1023-1031.
|
14. |
Rudno-Rudzińska J, Kielan W, Guziński M, et al. New therapeutic strategy: personalization of pancreatic cancer treatment-irreversible electroporation (IRE), electrochemotherapy (ECT) and calcium electroporation (CaEP)-a pilot preclinical study. Surg Oncol, 2021 Sep: 38: 101634. doi: 10.1016/j.suronc.2021.101634.
|
15. |
Cheng C, Xu M, Pan J, et al. A multicenter, randomized, parallel-controlled clinical trial protocol to evaluate the safety and efficacy of irreversible electroporation compared with radiofrequency ablation for the treatment of small hepatocellular carcinoma. World J Surg Oncol, 2024, 22(1): 332. doi: 10.1186/s12957-024-03614-z.
|
16. |
Martin RC, McFarland K, Ellis S, et al. Irreversible electroporation therapy in the management of locally advanced pancreatic adenocarcinoma. J Am Coll Surg, 2012, 215(3): 361-369.
|
17. |
Suraju OM, Su Y, Chang J, et al. Impact of irreversible electroporation on survival among patients with borderline resectable/locally advanced pancreatic cancer: a single center experience. Surgical Oncology Insight, 2024, 1(3): 100075. doi: 10.1016/j.soi.2024.100075.
|
18. |
Simmerman E, Chung J, Lawson A, et al. Application of irreversible electroporation ablation as adjunctive treatment for margin enhancement: safety and efficacy. J Surg Res, 2020, 246: 260-268.
|
19. |
Tasu JP, Herpe G, Damion J, et al. Irreversible electroporation to bring initially unresectable locally advanced pancreatic adenocarcinoma to surgery: the IRECAP phase II study. Eur Radiol, 2024, 34(10): 6885-6895.
|
20. |
Bhutiani N, Li Y, Zheng Q, et al. Electrochemotherapy with irreversible electroporation and FOLFIRINOX improves survival in murine models of Pancreatic Adenocarcinoma. Ann Surg Oncol, 2020, 27(11): 4348-4359.
|
21. |
Zeng J, Liu B, Lang X, et al. Clinical efficacy and safety of irreversible electroporation combined with chemotherapy in stage IV pancreatic cancer treatment. J Cancer Res Ther, 2024, 20(4): 1357-1361.
|
22. |
Ruarus AH, Vroomen LGPH, Geboers B, et al. Percutaneous irreversible electroporation in locally advanced and recurrent pancreatic cancer (PANFIRE-2): a multicenter, prospective, single-arm, phase II study. Radiology, 2020, 294(1): 212-220.
|
23. |
张通, 李晓勇, 陈艳军, 等. 不可逆电穿孔消融术联合程序性死亡蛋白-1抑制剂及化疗在局部进展期胰腺癌的临床疗效. 实用医学杂志, 2023, 39(9): 1153-1158.
|
24. |
马洋洋, 行艳丽, 李红梅, 等. 不可逆电穿孔同步化疗治疗局部进展性胰腺癌. 肝胆胰外科杂志, 2022, 34(10): 606-610.
|
25. |
Timmer FEF, Geboers B, Ruarus AH, et al. MRI-guided stereotactic ablative body radiotherapy versus CT-guided percutaneous irreversible electroporation for locally advanced pancreatic cancer (CROSSFIRE): a single-centre, open-label, randomised phase 2 trial. Lancet Gastroenterol Hepatol, 2024, 9(5): 448-459.
|
26. |
Lin YM. MRI-guided stereotactic ablative radiotherapy versus CT-guided irreversible electroporation in advanced pancreatic cancer: insights from the CROSSFIRE trial. Radiol Imaging Cancer, 2024, 6(3): e249010. doi: 10.1148/rycan.249010.
|
27. |
De Grandis MC, Ascenti V, Lanza C, et al. Locoregional therapies and remodeling of tumor microenvironment in pancreatic cancer. Int J Mol Sci, 2023, 24(16): 12681. doi: 10.3390/ijms241612681.
|
28. |
陈艳军, 程冰冰, 郜宇, 等. 纳米刀消融联合化疗/局部放疗对局部进展期胰腺癌的临床疗效. 中国现代普通外科进展, 2022, 25(11): 897-900.
|
29. |
Jiang L, Huang X, Hua X, et al. Treatment of locally advanced pancreatic cancer with irreversible electroporation and intraoperative radiotherapy. Hepatobiliary Surg Nutr, 2024, 13(6): 1087-1090.
|
30. |
Hong Y, Rice J, Sharma D, et al. The use of IRE in multi-modality treatment for oligometastatic pancreatic cancer. Am J Surg, 2018, 216(1): 106-110.
|
31. |
Peng H, Shen J, Long X, et al. Local release of TGF-β inhibitor modulates tumor-associated neutrophils and enhances pancreatic cancer response to combined irreversible electroporation and immunotherapy. Adv Sci (Weinh), 2022, 9(10): e2105240. doi: 10.1002/advs.202105240.
|
32. |
Kwon W, Thomas A, Kluger MD. Irreversible electroporation of locally advanced pancreatic cancer. Semin Oncol, 2021, 48(1): 84-94.
|
33. |
Justesen TF, Orhan A, Raskov H, et al. Electroporation and immunotherapy-unleashing the abscopal effect. Cancers (Basel), 2022, 14(12): 2876. doi: 10.3390/cancers14122876.
|
34. |
Lin M, Zhang X, Liang S, et al. Irreversible electroporation plus allogenic Vγ9Vδ2 T cells enhances antitumor effect for locally advanced pancreatic cancer patients. Signal Transduct Target Ther, 2020, 5(1): 215. doi: 10.1038/s41392-020-00260-1.
|
35. |
Slaughter JR, Burbach BJ, O’Flanagan SD, et al. Tumor ablation by irreversible electroporation (IRE) augments CTLA-4 checkpoint inhibitor immunotherapy. Journal of the American College of Surgeons, 2019, 229(4): e204. doi: 10.1016/j.jamcollsurg.2019.08.1298.
|
36. |
Beitel-White N, Martin RCG, Li Y, et al. Real-time prediction of patient immune cell modulation during irreversible electroporation therapy. Sci Rep, 2019, 9(1): 17739.
|
37. |
Sun SX, Liu Y, He CB, et al. Combining NanoKnife with M1 oncolytic virus enhances anticancer activity in pancreatic cancer. Cancer Letters, 2021, 502: 9-24.
|
38. |
Ma Y, Xing Y, Li H, et al. Irreversible electroporation combined with chemotherapy and PD-1/PD-L1 blockade enhanced antitumor immunity for locally advanced pancreatic cancer. Front Immunol, 2023, 14: 1193040. doi: 10.3389/fimmu.2023.1193040.
|
39. |
叶舰, 杨峻峰, 杜丽文, 等. 不可逆电穿孔联合免疫治疗对不可切除胰腺癌有效性和安全性的Meta分析. 临床肝胆病杂志, 2024, 40(11): 2277-2282.
|
40. |
Flak RV, Kofod-Olsen E, Sølvsten ND, et al. Pembrolizumab followed by irreversible electroporation of a liver metastasis in pancreatic cancer patients. iScience, 2024, 27(10): 111026. doi: 10.1016/j.isci.2024.111026.
|
41. |
蔡磊, 王先行, 王槐志. 胰腺癌免疫治疗的进展与瓶颈问题. 中国普外基础与临床杂志, 2023, 30(9): 1030-1036.
|
42. |
Liu Y, Zhang K, Cai X, et al. The role of IL-17, IFN-γ, 4-1BBL and tumour-infiltrating lymphocytes in the occurrence, development and prognosis of pancreatic cancer. Oncol Lett, 2024, 29(2): 88. doi: 10.3892/ol.2024.14834.
|
43. |
Shankara Narayanan JS, Hayashi T, Erdem S, et al. Treatment of pancreatic cancer with irreversible electroporation and intratumoral CD40 antibody stimulates systemic immune responses that inhibit liver metastasis in an orthotopic model. J Immunother Cancer, 2023, 11(1): e006133. doi: 10.1136/jitc-2022-006133.
|
44. |
Huang T, Wen X, Liang Y, et al. Irreversible electroporation-induced inflammation facilitates neutrophil-mediated drug delivery to enhance pancreatic cancer therapy. Mol Pharm, 2024, 21(4): 1998-2011.
|
45. |
Mercadal B, Beitel-White N, Aycock KN, et al. Dynamics of cell death after conventional IRE and H-FIRE treatments. Ann Biomed Eng, 2020, 48(5): 1451-1462.
|
46. |
Rai ZL, Feakins R, Pallett LJ, et al. Irreversible electroporation (IRE) in locally advanced pancreatic cancer: a review of current clinical outcomes, mechanism of action and opportunities for synergistic therapy. J Clin Med, 2021, 10(8): 1609. doi: 10.3390/jcm10081609.
|